More fundamental and creative research is needed to to fill in the gaps in HIV vaccine research, said Dr. Françoise Barré-Sinoussi, Institut Pasteur, France, at the 16th International AIDS Conference, Toronto, Canada.
According to Dr. Barré-Sinoussi there have been 85 HIV vaccine trials with over 30 different candidates. Yet we are no closer to finding out whether a protective HIV vaccine is feasible or not.
Barré-Sinoussi said that recent advances in fundamental immunology have provided the greatest hope towards progressing to a new and effective vaccine. These include new findings related to our body's innate immunity as well as the vital role played by it in the response to HIV exposure.
Barré-Sinoussi also stressed the importance of future research into the therapeutic vaccination of HIV-infected patients on highly active antiretroviral therapy (HAART).